Lumoxiti, which is a CD22-directed cytotoxin, has been approved for the patients who had two or prior systemic therapies, including treatment with a purine nucleoside analog. AstraZeneca executive
The post AstraZeneca secures FDA approval for Lumoxiti to treat hairy cell leukaemia appeared first on Pharma Business review.